From: The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe
Number | % of total patients | Rate/100 PYE (95% CI) | |
---|---|---|---|
QT C prolongation | 15 * | 1.05 | 0.85 (0.48–1.41) |
"Before" group | 10 | 0.70 | 0.67 (0.32–1.23) |
"After" group | 3 | 0.21 | 1.15 (0.24–3.37) |